Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Drug Therapy for Rheumatoid Arthritis in Adults

Slide: 23 of 45

Comparisons of Biologic DMARDs Across Controlled Studies: Mixed Treatment Comparisons

The authors of the comparative effectiveness review used data from placebo-controlled trials to compare biologic disease-modifying anti-rheumatic drugs (DMARDs) across studies, using an analytic method called a “mixed treatment comparison.” The patient populations in the studies had methotrexate-resistant rheumatoid arthritis. The outcome analyzed was the rate of achieving the American College of Rheumatology 50-percent response criteria (ACR50). Thirty placebo controlled trials with a total of 6,888 patients included the biologic DMARDs abatacept, adalimumab, anakinra, etanercept, golimumab, infliximab, rituximab, and tocilizumab. The analysis demonstrated that etanercept yields the greatest ACR50 response when compared with other biologics and that anakinra yields the lowest. However, the strength of evidence is low, as the comparisons are indirect.